University College London Hospitals NHS Foundation Trust

A technique to improve the precision of prostate cancer surgery means that almost twice as many men preserve their erectile function compared to those undergoing standard surgery, according to results from a clinical trial led by UCLH and UCL. UCLH consultant urologist Professor Greg Shaw said: “Our results show that, by using NeuroSAFE, nearly twice as many men don’t have to face potentially life-changing loss of erectile function after prostate surgery. It is an involved procedure that requires expertise, but it isn’t expensive, particularly given the benefits it offers for patients, and most importantly doesn’t jeopardise cancer control. “NeuroSAFE wouldn’t be appropriate for all patients, as many can safely have nerve-sparing surgery using standard robotic techniques. But for younger patients and those who wouldn’t normally be seen as eligible for nerve-sparing surgery, it offers them a greater chance to hold onto their quality of life.” Find out more about the NeuroSAFE PROOF trial: https://lnkd.in/eQMQhHt7

We are pleased to announce that three UCLH projects have been shortlisted across two categories at the #HSJDigitalAwards 2025. We are finalists for: - Moving Towards Net Zero through Digital - Digital Clinical Safety UCLH chief executive David Probert said: “Digital is hugely important to the way we plan and deliver services and moving from analogue to digital is a key priority for all NHS organisations. I’m really proud of the way we’re embracing digital approaches to healthcare at UCLH, and having three projects shortlisted for these awards is a great credit to the teams throughout UCLH that are working hard and innovating to ensure we’re using new technology to improve the care we offer patients, make UCLH a better place to work and better for the environment.” The winners will be announced at a ceremony on 26 June 2025 at the ICC, Birmingham. All the best of luck to the UCLH teams shortlisted! Find out more: https://buff.ly/mhZuahy #OneTeam

“I feel a great sense of pride when I say I work for the NHS. I can’t see myself doing anything other than this.” This Healthcare Science Week, meet Callum, a UCLH proton therapy physicist. Proton beam therapy (PBT) plays a key role in cancer treatment. It delivers a precise beam of high energy protons to target and treat highly specific types of cancer. In this video, Callum talks more about the role of proton therapy physicists and the life-changing work they do every day for cancer patients. If you’re passionate about a career in science and technology that can have a life-changing impact on patients, search ‘NHS healthcare science careers’ to find out more. #HCSW2025 #HealthcareScience #NHS #ProtonTherapy #ScienceCareers

For the third year running, we've received the highest score of all general acute and acute/community NHS trusts in England for staff that would recommend us as a place to work! Thank you to everyone who took the time to complete the NHS Staff Survey 2024. Read more: https://buff.ly/FRKlavL #OneTeam #uclh #nhs #staff #london #healthcare #news

This #NationalCancerCNSDay, we welcome Sonya Moudart, our new clinical nurse specialist at UCLH who will be supporting asbestos-related cancer patients across North Central London Cancer Alliance. Sonya has worked in #cancer care for 30 years, including 23 years as a clinical nurse specialist. Commenting on her appointment, Sonya said: “I have chosen to come back to a nurse specialist role and am delighted that this will be with Mesothelioma UK. "I’m looking forward to working with my nursing colleagues to raise awareness and to support patients and their families." Read more: https://buff.ly/g5fxAmt #oneteam #CancerCNSDay #healthcare #nhs

A new service to provide comprehensive care and support for patients living with #SickleCell disorder is now available in the comfort of their homes thanks to a partnership between UCLH and Whittington Health. Consultant haematologist Perla Eleftheriou said: “We’re hoping that for some sickle cell patients, the UCLH@home pathway will speed up safe discharge, meaning they can get home sooner while minimising the risk of readmission.” Read the full story here: https://buff.ly/zVvtwCr #nhs #sicklecell #healthcare

"'Accelerate Action' marks the continuous strides taken to remove bias and gender inequality for women in many areas. Although there is still some way to go to fully achieve this, together as a network we will continue to create an inclusive workplace." This #InternationalWomensDay, the UCLH Women's Network held a series of events emphasising this year's theme #AccelerateAction - sharing awareness on gender equality and discussing the steps needed to break down barriers, with a goal of achieving lasting change and impact at UCLH. UCLH Women's Network co-chairs Innica Halsey and Shirley Parker said: "'Accelerate Action' means actively driving meaningful change by creating an environment where women are empowered to lead, innovate, and succeed. "It’s about trying to fast-track initiatives that promote gender equality, dismantling barriers that hold women back, and ensuring that progress is not just a goal but a continuous priority. "Through collaboration, advocacy, and bold leadership, we believe we can make a lasting impact." #IWD2025 #oneteam 💜 #nhs

We are proud to support women’s health at #UCLH this #InternationalWomensDay. Find out more about us by visiting our website: https://buff.ly/jKPBpD7 #OneTeam #TogetherWeCanDoMore #IWD

UCLH researchers have found that a surgical operation may help patients who lost their sense of smell after contracting #COVID19. Early #research has shown that a septorhinoplasty can help kickstart recovery by improving nasal airflow. Penelope (pictured right), a participant in the trial said: “Before I had the surgery on my nose, I had begun to accept that I would probably never be able to smell or taste things the way I used to. “My taste and smell have almost returned to normal - I'm not sure if it will ever fully return as I still have a small reduction in it, but I am so glad that I am no longer as isolated as I once was. I will never take my senses for grated ever again.” Read the full story here: https://buff.ly/X3goWK8 #longcovid #coronovirus #covid #nhs #healthcare #nhs

A researcher from University College London Hospitals NHS Foundation Trust and UCL who helped deliver the first-ever treatment for the rare neurodegenerative disease Friedrich’s ataxia has won a UCL award for her collaboration with industry to bring the treatment to patients. Professor Paola Giunti, who has been supported by the NIHR (National Institute for Health and Care Research) UCLH Biomedical Research Centre, received the ‘Impactful Partnership with Industry’ award at a ceremony earlier this month, for the instrumental role her team had in validating the drug, and the global clinical trial of the drug alongside Reata Pharmaceuticals – now Biogen. FA is a rare, inherited neurodegenerative disease, affecting about 22,000 people worldwide. It typically emerges in childhood and causes progressive loss of coordination, muscle weakness, and fatigue, often leading to wheelchair reliance, and premature death. The trial recruited participants from the US, Europe, and Australia. Patients at UCLH took part at the NIHR Clinical Research Facility at UCLH. Prof Giunti, who is Head of the UCLH Ataxia Centre, said: "I am very honoured to be recognised by this award and to have experienced such a longstanding partnership with industry to impact the life of my patients. I always work with patients who have been at the centre of my studies and clinical service, and to see them directly benefit from this research that came directly from the Ataxia Centre is what gives me my drive and purpose."